LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis
LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with temtokibart, an investigational IL-22RA1 antagonist, for the potential treatment of adults with moderate-to-severe atopic dermatitis (AD).
The study was a phase 2b, randomized, double-blind, placebo-controlled, multi-site, parallel-group, dose-finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered temtokibart, also called LEO 138559, in adult subjects with moderate-to-severe AD. 1
The phase 2b trial achieved positive results for the primary endpoint based on percentage change in EASI (Eczema Area and Severity Index) from baseline to Week 16 for 3 highest doses in adults with moderate-to-severe AD. The treatment was generally well-tolerated, with no dose dependency, and the majority of adverse events observed were non-serious, mild or moderate in severity, and not considered treatment related.
' Atopic dermatitis is a complex immunological condition, and patients living with this debilitating disease still face unmet needs. LEO Pharma is committed to making a fundamental difference for these patients, and we are encouraged by the results of this phase 2b trial, which has explored how to target the disease from a different angle with a different mechanism of action, compared to what is commonly used today to treat AD,' said Dr Jacob Pontoppidan Thyssen, Chief Scientific Officer & Executive Vice President, Science, Search & Innovation at LEO Pharma. ' These results further add to the understanding of the mode of action of temtokibart and its potential abilities to address unmet needs in diseases where the IL-22 pathway is known to play a key role – in medical dermatology and beyond.'
Temtokibart is an investigational monoclonal antibody for the treatment of moderate-to-severe AD, which blocks the IL-22RA1 receptor subunit thereby inhibiting the effect of the interleukin-22 (IL-22) cytokine – known to be elevated in patients with atopic dermatitis. 2-4
LEO Pharma and argenx, a global immunology company, formed a strategic alliance in 2015 to develop innovative antibody-based solutions for the treatment of chronic inflammation that underlies many skin conditions. LEO Pharma and argenx jointly developed temtokibart under this research agreement and LEO Pharma has subsequently obtained the exclusive license to develop and commercialize temtokibart.
LEO Pharma is currently collecting and evaluating the full data set. Detailed results from the phase 2b trial are planned to be submitted for scientific presentation and publication at a later date.
For more information on the trial (NCT05923099) go to clinicaltrials.gov.
About the Phase 2b trial
The temtokibart phase 2b trial (NCT05923099) is a randomized, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered temtokibart in adult patients with moderate-to-severe atopic dermatitits. 1 Patients were randomized to receive one of four doses of temtokibart or placebo. 1 The primary endpoint is percent change in EASI from baseline to Week 16. 1 The key secondary endpoint is number of treatment-emergent adverse events from baseline to Week 16 per subject. 1
About atopic dermatitis
Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions. 5 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation. 6 Type 2 cytokines, including IL-13, play an important role in the key aspects of atopic dermatitis pathophysiology. 7,8 Excessive IL-22 production is also known to contribute to the pathogenesis of AD. 9,10
About investigational temtokibart
Temtokibart is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis. 3,4 It blocks the IL-22RA1 subunit and thereby inhibits the effects of the IL-22 cytokine, and also the effects of IL-20 and IL-24 signaling. 3,4 Temtokibart does not bind to the IL-22 cytokine itself. 3,4 LEO Pharma has obtained a worldwide exclusive license to develop and commercialize temtokibart from argenx.
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.
References
NCT05923099. Available at: clinicaltrials.gov/study/NCT05923099. Accessed September 2024.
Bangert C, et al. Presented at European Academy of Dermatology & Venereology (EADV) 2024 Annual Meeting, Amsterdam, 25–28 September 2024.
Thaçi D, et al. Presented at American Academy of Dermatology (AAD) 2023 Annual Meeting, New Orleans, 17–21 March 2023.
Thaçi D, et al. Presented at European Academy of Dermatology and Venereology (EADV) 2023 Annual Meeting, Berlin, 11–13 October 2023.
Weidinger S, et al. Lancet 2016;387:1109–1122.
Boguniewicz M, et al. Immunol Rev 2011;242:233–246.
Tubau C, Puig L. Immunotherapy 2021;13:327–344.
Bieber T. Allergy 2020;75:54–62.
Gittler JK, et al. J Allergy Clin Immunol 2012;130:1344–1354.
Nograles K, et al. J Allergy Clin Immunol 2009;123:1244–1252.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Business Wire
a day ago
- Business Wire
MedCity News Report Reveals Employers are Turning to AI-Powered, Clinically Integrated Independent Healthcare Navigation to Combat Rising Costs
DUBLIN, Ohio--(BUSINESS WIRE)--As employers face mounting pressure to improve health outcomes while managing rising costs, a new report sponsored by Quantum Health reveals a significant shift in how benefit consultants are advising self-insured employers to build and evaluate healthcare benefit strategies. The 2025 Benefits Sentiment Index, conducted in partnership with MedCity News, offers a data driven look into the top challenges and emerging priorities shaping the benefits landscape. "Independent navigation is accelerating as a central benefits strategy, not only to improve the member experience, but to lower costs, improve value on investment and seamlessly integrate AI-driven innovations with compassionate, human-centered care." Share Now in its third year, the Index surveyed more than 120 experienced benefit consultants and uncovered a growing demand for independent, clinically integrated navigation models and a rising dissatisfaction with traditional carrier-provided services. Among the key findings: 68% of surveyed consultants guide clients away from navigation solutions tied to insurance carriers, instead recommending independent partners citing the need for a stronger member experience, clinical integration and transparency in cost savings. 87% of surveyed consultants report advising on GLP-1 drug coverage, with most recommending restrictions and measurable outcomes to ensure cost-effectiveness. The influence of AI continues to grow, with 72% of consultants surveyed counseling clients on its use in benefits — up significantly from the prior year. 'We're excited to once again collaborate with MedCity News on the Benefits Sentiment Index, bringing forward the key priorities shaping the healthcare benefits landscape,' said Dayne Williams, CEO of Quantum Health. 'This year's findings highlight how independent healthcare navigation is accelerating as a central healthcare benefits strategy — not only to simplify and improve the member healthcare experience, but also to lower costs, improve value on investment and seamlessly integrate AI-driven innovations with compassionate, human-centered care.' Williams added, "As the only navigation solution that engages continuously with providers from the member's first moment of need, we take immediate action to guide care decisions in real time. Leveraging advanced AI and our proprietary Real-Time Intercept® platform, we proactively identify members at critical moments and connect them to the right care at the right time. This approach combines clinical expertise with accelerated intervention — delivering independently validated results, improved health outcomes and a better experience for members.' The report also calls attention to gaps in engagement and personalization, with half of consultants reporting that their clients struggle with fragmented care coordination, lack of centralized access and difficulty engaging employees. Consultants are increasingly seeking solutions that integrate clinical care teams, embed AI for proactive risk detection, and provide seamless connections to behavioral health and social determinants of health support. 'At MedCity News, we're committed to surfacing insights that drive smarter healthcare decisions, and this year's Index does exactly that,' said Ken Montgomery, publisher of MedCity News. 'The data reveals a clear call to action: self-insured employers and their consultants are demanding more from navigation solutions — more clinical integration, more actionable data and more alignment with evolving technologies like AI. We're proud to partner with Quantum Health to spotlight these critical shifts and help advance the conversation on what effective benefits strategy looks like today.' 'The takeaway is clear,' said Williams. 'Employers are no longer satisfied with the status quo. The next chapter of healthcare navigation must be clinically integrated, AI-enabled and relentlessly focused on driving measurable results.' The full 2025 Benefits Sentiment Index is available for download here. About MedCity News MedCity News is the go-to digital destination for B2B healthcare innovation news, informing decision-makers of trends in the healthcare industry. MedCity News produces dynamic and unique innovation-focused events for the entire healthcare ecosystem, gathering experts from across disciplines to address the challenges facing the industry. MedCity News also produces the Debunked videocast, as well as several podcasts: MedCity Pivot, MedCity Moves and MedCity FemFwd. MedCity News is owned by Breaking Media, a network of websites, e-newsletters, events and social media channels for influential, affluent business communities. To learn more visit MedCity News. About Quantum Health Celebrating 25 years of innovation, Quantum Health is a leading consumer healthcare navigation and care coordination company. Its Real-Time Intercept® platform identifies early intervention opportunities to improve engagement, outcomes, and cost efficiency. Based in Dublin, Ohio, Quantum Health has earned national recognition for growth and workplace culture, including honors from FORTUNE, Inc. 5000, and the Women Presidents' Organization. To learn more, visit and connect on LinkedIn.
Business Wire
a day ago
- Business Wire
Nu-Tek BioSciences Brings Animal-Free Cell Culture and Fermentation Solutions to BPI East 2025
MINNETONKA, Minn--(BUSINESS WIRE)--Nu-Tek BioSciences, a leading provider of high-performance, 100% animal-free peptones and specialty yeast extracts, announced its participation in next month's BioProcess International (BPI) East Conference & Exhibition. The event will take place from September 15-18, 2025, at the Hynes Convention Center in Boston, MA. Biomanufacturers are invited to connect with Nu-Tek BioSciences to discover their critical ingredients for advancing cell culture and industrial fermentation. Nu-Tek's 100% animal-free cell culture and fermentation ingredients are critical to develop today's leading pharmaceutical products. Share Nu-Tek BioSciences directly supports global biopharmaceutical manufacturers with innovative and sustainable raw materials. The company leverages their purpose-built, dedicated facility to manufacture premium quality peptones and yeast extracts, ensuring consistent quality, supply chain security, and the elimination of risks associated with animal-derived components. "BPI East is an invaluable platform for us to engage with biomanufacturers seeking to optimize their cell culture and industrial fermentation processes," said Chris Wiedel, Chief Business Officer for Nu-Tek BioSciences. "Our 100% animal-free ingredients are designed to meet the rigorous demands of modern biomanufacturing. We look forward to discussing how our products and variability reduction programs support the development and at-scale manufacturing of groundbreaking therapeutics." The Nu-Tek team will be available to provide insights into how Nu-Tek's ingredients enhance cell growth, improve yields, and streamline bioprocessing workflows. More information about Nu-Tek BioSciences products and services can be found at About Nu-Tek BioSciences: Nu-Tek BioSciences is a market leader in the development and manufacturing of high-quality, 100% animal-origin-free (AOF) peptones and protein hydrolysates. Headquartered in Minnetonka, Minnesota, the company operates a state-of-the-art, purpose-built manufacturing facility dedicated to producing superior raw materials for the biopharmaceutical industry. Nu-Tek's innovative solutions are essential for cell culture and microbial fermentation, supporting the production of vaccines, therapeutics, and other vital biologics.
